| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Lynn L Silver | Q56530439 |
| P2093 | author name string | Lynn L Silver | |
| P2860 | cites work | Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence | Q22122411 |
| Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms | Q24519040 | ||
| Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective | Q24535810 | ||
| Functional, biophysical, and structural bases for antibacterial activity of tigecycline | Q24548264 | ||
| Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance | Q24548472 | ||
| RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases | Q24554345 | ||
| Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus | Q24556635 | ||
| Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase | Q24567584 | ||
| Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics | Q27627265 | ||
| The structures of four macrolide antibiotics bound to the large ribosomal subunit | Q27639442 | ||
| The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography | Q27640718 | ||
| Structural Insight into the Antibiotic Action of Telithromycin against Resistant Mutants | Q27641602 | ||
| Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus | Q28062241 | ||
| Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update | Q28143206 | ||
| The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase | Q28217168 | ||
| Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs | Q28253138 | ||
| The interaction between coumarin drugs and DNA gyrase | Q28256018 | ||
| Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. | Q28379520 | ||
| Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors | Q33234000 | ||
| Two active forms of UDP-N-acetylglucosamine enolpyruvyl transferase in gram-positive bacteria | Q33601835 | ||
| In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae. | Q40469366 | ||
| Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity | Q40621197 | ||
| Inactivation of antibiotics and the dissemination of resistance genes | Q40737331 | ||
| Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). | Q40882661 | ||
| In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci | Q41269617 | ||
| Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates | Q42106186 | ||
| Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. | Q42112490 | ||
| The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria | Q43424166 | ||
| Design of novel antibiotics that bind to the ribosomal acyltransfer site | Q43934962 | ||
| Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species | Q44144332 | ||
| High Rate of Macrolide Resistance inStaphylococcus aureusStrains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains | Q44195004 | ||
| Structure–activity relationship in the oxazolidinone–quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action | Q44658903 | ||
| Epidemiology of macrolide and/or lincosamide resistant Streptococcus pneumoniae clinical isolates with ribosomal mutations | Q44890372 | ||
| The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus | Q44958662 | ||
| In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. | Q45004641 | ||
| Targeting extracellular pyrophosphates underpins the high selectivity of nisin | Q45171526 | ||
| Active site directed inhibitors of replication-specific bacterial DNA polymerases | Q45234316 | ||
| Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance | Q46455040 | ||
| A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. | Q46642614 | ||
| Synthesis and antibacterial activity of 3-substituted-6-(3-ethyl-4-methylanilino)uracils | Q46775793 | ||
| Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome | Q47208727 | ||
| Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones | Q48080383 | ||
| Evolution of penicillin resistance in Streptococcus pneumoniae; the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae | Q48106945 | ||
| Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA. | Q54092195 | ||
| Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. | Q54099400 | ||
| The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. | Q54104684 | ||
| RO 23-9424, a new cephalosporin 3'-quinolone: in-vitro antimicrobial activity and tentative disc diffusion interpretive criteria. | Q54251165 | ||
| DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. | Q54588445 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| 1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents | Q62580325 | ||
| Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population | Q71237046 | ||
| Ketolides lack inducibility properties of MLS(B) resistance phenotype | Q73568566 | ||
| Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals | Q73741500 | ||
| Clinical and laboratory studies of novobiocin, a new antibiotic | Q74125687 | ||
| Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis | Q39658106 | ||
| Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethyl-4'-methylanilino) uracil | Q39671152 | ||
| Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. | Q39731888 | ||
| Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus | Q39780047 | ||
| Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance | Q39841944 | ||
| Discovery and development of new antibiotics: the problem of antibiotic resistance | Q39865095 | ||
| MECHANISM OF ACTION OF NALIDIXIC ACID ON ESCHERICHIA COLI.II. INHIBITION OF DEOXYRIBONUCLEIC ACID SYNTHESIS. | Q40250988 | ||
| Penicillin-binding proteins in bacteria | Q40282477 | ||
| Protein synthesis as a target for antibacterial drugs: current status and future opportunities | Q40408978 | ||
| Topoisomerase IV is a target of quinolones in Escherichia coli | Q33724600 | ||
| Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin | Q33770013 | ||
| Penicillin: its basic site of action as an inhibitor of a peptide cross-linking reaction in cell wall mucopeptide synthesis | Q33803831 | ||
| Biological characterization of novel inhibitors of the gram-positive DNA polymerase IIIC enzyme | Q33857079 | ||
| In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem | Q33938036 | ||
| Mutation frequencies and antibiotic resistance | Q33945503 | ||
| Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage | Q33980212 | ||
| In vitro antimicrobial activities of novel anilinouracils which selectively inhibit DNA polymerase III of gram-positive bacteria | Q33980353 | ||
| Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci | Q33982606 | ||
| Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition | Q33983660 | ||
| DNA gyrase: an enzyme that introduces superhelical turns into DNA | Q34013173 | ||
| Estimating the relative contributions of mutation and recombination to clonal diversification: a comparison between Neisseria meningitidis and Streptococcus pneumoniae | Q34015665 | ||
| Mechanisms of action and resistance of older and newer fluoroquinolones | Q34030757 | ||
| Transferable vancomycin and teicoplanin resistance in Enterococcus faecium | Q34042099 | ||
| Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation | Q34063864 | ||
| Mining bacterial genomes for antimicrobial targets | Q34094923 | ||
| Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae | Q34104600 | ||
| Origin and evolution of the AmpC beta-lactamases of Citrobacter freundii | Q34107174 | ||
| Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides | Q34112287 | ||
| Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria | Q34277300 | ||
| rrndb: the Ribosomal RNA Operon Copy Number Database | Q34314931 | ||
| Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli | Q34323549 | ||
| Resistance to antibiotics mediated by target alterations | Q34339223 | ||
| Structure-activity relationships of ketolides vs. macrolides | Q34347128 | ||
| Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies | Q34347864 | ||
| Ramoplanin: a lipoglycodepsipeptide antibiotic | Q34405651 | ||
| Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus | Q34446438 | ||
| Exploiting genomics to discover new antibiotics | Q34453460 | ||
| Structure-based drug design meets the ribosome | Q34489129 | ||
| In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class | Q34510396 | ||
| Structure, biochemistry and mechanism of action of glycopeptide antibiotics | Q34665729 | ||
| Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus | Q34680589 | ||
| The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics | Q34721545 | ||
| Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study | Q35014369 | ||
| Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase | Q35042255 | ||
| Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme | Q35059616 | ||
| Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity | Q35059655 | ||
| Distinct penicillin binding proteins involved in the division, elongation, and shape of Escherichia coli K12 | Q35085145 | ||
| Inhibition of a DNA Polymerase from Bacillus subtilis by Hydroxyphenylazopyrimidines | Q35093477 | ||
| Hydroxyphenylazopyrimidines: Characterization of the Active Forms and Their Inhibitory Action on a DNA Polymerase from Bacillus subtilis | Q35096531 | ||
| Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. | Q35126142 | ||
| Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus | Q35166213 | ||
| Antibiotic resistance mutations in 16S and 23S ribosomal RNA genes ofEscherichia coli | Q35284526 | ||
| Biological costs and mechanisms of fosfomycin resistance in Escherichia coli | Q35685710 | ||
| Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth | Q35718618 | ||
| Mechanisms of action of cephalosporin 3'-quinolone esters, carbamates, and tertiary amines in Escherichia coli | Q35810503 | ||
| When will the genomics investment pay off for antibacterial discovery? | Q36357524 | ||
| Glycopeptides: Update on an old successful antibiotic class | Q36368315 | ||
| Use of genomics to select antibacterial targets | Q36368319 | ||
| Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine | Q36369306 | ||
| Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine | Q36379261 | ||
| Crystallizing new approaches for antimicrobial drug discovery | Q36387136 | ||
| Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. | Q36409465 | ||
| Ceftobiprole: in-vivo profile of a bactericidal cephalosporin | Q36416472 | ||
| Tigecycline: a critical analysis | Q36534862 | ||
| Anti-MRSA beta-lactams in development | Q36561331 | ||
| Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424 | Q36753777 | ||
| Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives | Q37092384 | ||
| In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models | Q37734457 | ||
| Screening of natural products for antimicrobial agents. | Q37977577 | ||
| Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392. | Q39117998 | ||
| Primary targets of fluoroquinolones in Streptococcus pneumoniae. | Q39469902 | ||
| Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America | Q39475725 | ||
| In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus | Q39476686 | ||
| Cloning, characterization, and inactivation of the gene pbpC, encoding penicillin-binding protein 3 of Staphylococcus aureus | Q39499081 | ||
| Recruitment of the mecA gene homologue of Staphylococcus sciuri into a resistance determinant and expression of the resistant phenotype in Staphylococcus aureus. | Q39503313 | ||
| Complementation of the essential peptidoglycan transpeptidase function of penicillin-binding protein 2 (PBP2) by the drug resistance protein PBP2A in Staphylococcus aureus | Q39505138 | ||
| Isolation and characterisation of a strain carrying a conditional lethal mutation in the cou gene of Escherichia coli K12 | Q39588522 | ||
| On the nature of antibiotic binding sites in ribosomes | Q39599757 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 41-55 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Multi-targeting by monotherapeutic antibacterials | |
| P478 | volume | 6 |
| Q28481777 | 6-Arylpyrido[2,3-d]pyrimidines as novel ATP-competitive inhibitors of bacterial D-alanine:D-alanine ligase |
| Q44105963 | A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment. |
| Q35170621 | A detailed study of antibacterial 3-acyltetramic acids and 3-acylpiperidine-2,4-diones. |
| Q34135985 | A genome-wide inducible phenotypic screen identifies antisense RNA constructs silencing Escherichia coli essential genes |
| Q49912940 | A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK. |
| Q57461268 | A pathway-directed screen for inhibitors of the bacterial cell elongation machinery |
| Q28482361 | A systems biology approach to drug targets in Pseudomonas aeruginosa biofilm |
| Q52655525 | Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens? |
| Q40678760 | Antimicrobial Properties of Diamond-Like Carbon/Silver Nanocomposite Thin Films Deposited on Textiles: Towards Smart Bandages. |
| Q46493036 | Appropriate Targets for Antibacterial Drugs |
| Q34619268 | Are natural products still the best source for antibacterial discovery? The bacterial entry factor. |
| Q38964523 | Bacterial fatty acid metabolism in modern antibiotic discovery |
| Q36982025 | Bacterial genome sequencing and its use in infectious diseases |
| Q34412978 | Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations |
| Q26829707 | Can we prevent antimicrobial resistance by using antimicrobials better? |
| Q33793074 | Challenges of antibacterial discovery |
| Q36914997 | Combating bacteria and drug resistance by inhibiting mechanisms of persistence and adaptation. |
| Q90100518 | Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes |
| Q59197547 | Current and Emerging Approaches to Engineer Antibacterial and Antifouling Electrospun Nanofibers |
| Q38838150 | Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells |
| Q37673735 | Dense genomic sampling identifies highways of pneumococcal recombination |
| Q37335513 | Development of a one-pot assay for screening and identification of Mur pathway inhibitors in Mycobacterium tuberculosis |
| Q55348060 | Directed evolution of multiple genomic loci allows the prediction of antibiotic resistance. |
| Q90999366 | Discovery of dual-activity small-molecule ligands of Pseudomonas aeruginosa LpxA and LpxD using SPR and X-ray crystallography |
| Q24674719 | Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties |
| Q62673364 | Drug combinations: a strategy to extend the life of antibiotics in the 21st century |
| Q43473553 | Evaluation of WO2012177707 and WO2012097269: Vertex's phosphate prodrugs of gyrase and topoisomerase antibacterial agents |
| Q39408643 | Exogenous fatty acid metabolism in bacteria |
| Q34466407 | Genome-wide enrichment screening reveals multiple targets and resistance genes for triclosan in Escherichia coli |
| Q35759365 | High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU. |
| Q102075548 | Improving target assessment in biomedical research: the GOT-IT recommendations |
| Q35005092 | In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens |
| Q36192633 | In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media |
| Q60045950 | Insight into Elongation Stages of Peptidoglycan Processing in Bacterial Cytoplasmic Membranes |
| Q34627247 | Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery |
| Q27667190 | Interception of teicoplanin oxidation intermediates yields new antimicrobial scaffolds |
| Q43077045 | Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline |
| Q28069433 | Lead Discovery Strategies for Identification of Chlamydia pneumoniae Inhibitors |
| Q27485405 | Learning from the past for TB drug discovery in the future |
| Q28818404 | Legionella shows a diverse secondary metabolism dependent on a broad spectrum Sfp-type phosphopantetheinyl transferase |
| Q92682023 | Ligands and Receptors with Broad Binding Capabilities Have Common Structural Characteristics: An Antibiotic Design Perspective |
| Q41980687 | Lipodepsipeptide empedopeptin inhibits cell wall biosynthesis through Ca2+-dependent complex formation with peptidoglycan precursors |
| Q36276904 | Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition |
| Q83265745 | Mechanisms of drug combinations: interaction and network perspectives |
| Q35060154 | Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action |
| Q37962486 | Metabolic network modeling and simulation for drug targeting and discovery |
| Q90192897 | Multitarget Approaches against Multiresistant Superbugs |
| Q33854785 | Multitarget drug discovery for tuberculosis and other infectious diseases |
| Q41823306 | MurF inhibitors with antibacterial activity: effect on muropeptide levels |
| Q34000399 | N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry |
| Q80546533 | Naphthyl tetronic acids as multi-target inhibitors of bacterial peptidoglycan biosynthesis |
| Q27650891 | Natural product juglone targets three key enzymes from Helicobacter pylori: inhibition assay with crystal structure characterization |
| Q38620371 | Natural products as a source of drug leads to overcome drug resistance |
| Q36153263 | New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development. |
| Q39768207 | Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay |
| Q33917913 | Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. |
| Q42148578 | Novel inhibitors of the Pseudomonas aeruginosa virulence factor LasB: a potential therapeutic approach for the attenuation of virulence mechanisms in pseudomonal infection |
| Q81294612 | On the absolute configuration in 1,4-dihydrothiazepine covalent complexes derived from inhibition of class A and C beta-lactamases with 6-methylidene penems |
| Q59070982 | Optimized arylomycins are a new class of Gram-negative antibiotics |
| Q51817746 | Pathway sensitivity analysis for detecting pro-proliferation activities of oncogenes and tumor suppressors of epidermal growth factor receptor-extracellular signal-regulated protein kinase pathway at altered protein levels. |
| Q40192107 | Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics |
| Q36198580 | Platensimycin and platencin: Inspirations for chemistry, biology, enzymology, and medicine |
| Q33745572 | Postgenomic strategies in antibacterial drug discovery. |
| Q37593264 | Predicting Drug Combination Index and Simulating the Network-Regulation Dynamics by Mathematical Modeling of Drug-Targeted EGFR-ERK Signaling Pathway |
| Q37595559 | Quinolones: action and resistance updated |
| Q92999174 | Rapid Evolution of Reduced Susceptibility against a Balanced Dual-Targeting Antibiotic through Stepping-Stone Mutations |
| Q39755688 | Rapid Inhibition Profiling in Bacillus subtilis to Identify the Mechanism of Action of New Antimicrobials |
| Q30400724 | Rapid analysis of pharmacology for infectious diseases |
| Q40187481 | Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors. |
| Q28069943 | Resistance Mechanisms and the Future of Bacterial Enoyl-Acyl Carrier Protein Reductase (FabI) Antibiotics |
| Q28650583 | Resistance-resistant antibiotics |
| Q34454606 | Screen for agents that induce autolysis in Bacillus subtilis |
| Q27701752 | Structure of shikimate kinase, an in vivo essential metabolic enzyme in the nosocomial pathogen Acinetobacter baumannii, in complex with shikimate |
| Q38765020 | Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses |
| Q39096288 | Synthesis, Structure, and SAR of Tetrahydropyran-Based LpxC Inhibitors |
| Q41194288 | Targeting Multiple Aminoacyl-tRNA Synthetases Overcomes the Resistance Liabilities Associated with Antibacterial Inhibitors Acting on a Single Such Enzyme |
| Q28492792 | Targeting a bacterial stress response to enhance antibiotic action |
| Q38919751 | Targeting bactoprenol-coupled cell envelope precursors |
| Q26829884 | The Dialogue of the Host-Parasite Relationship: Leishmania spp. and Trypanosoma cruzi Infection |
| Q27684359 | The Role of a Novel Auxiliary Pocket in Bacterial Phenylalanyl-tRNA Synthetase Druggability |
| Q40519553 | The evolution of antimicrobial peptide resistance in Pseudomonas aeruginosa is shaped by strong epistatic interactions |
| Q26995817 | The pharmacological landscape and therapeutic potential of serine hydrolases |
| Q29619404 | The spectrum of latent tuberculosis: rethinking the biology and intervention strategies |
| Q33992683 | The structure-activity relationship of urea derivatives as anti-tuberculosis agents |
| Q57492054 | Therapeutic Targets in Chlamydial Fatty Acid and Phospholipid Synthesis |
| Q64098572 | Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance |
| Q24289511 | Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples |
| Q28486248 | Transcriptional profiles of the response of methicillin-resistant Staphylococcus aureus to pentacyclic triterpenoids |
| Q98726494 | Venom peptides in association with standard drugs: a novel strategy for combating antibiotic resistance - an overview |
| Q38070780 | Viable screening targets related to the bacterial cell wall. |
| Q58215959 | Virtual screening for potential inhibitors of bacterial MurC and MurD ligases |
| Q28485360 | What does it take to synergistically combine sub-potent natural products into drug-level potent combinations? |
Search more.